The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer | Zendy

Lynsey Devlin | Zendy; L. Grocutt | Zendy; Bianca Hunter | Zendy; H. Chemu | Zendy; A. Duffton | Zendy; Alec McDonald | Zendy; Nicholas MacLeod | Zendy; Philip McLoone | Zendy; Séan M. O’Cathail | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer

Author(s) -

Lynsey Devlin,

L. Grocutt,

Bianca Hunter,

H. Chemu,

A. Duffton,

Alec McDonald,

Nicholas MacLeod,

Philip McLoone,

Séan M. O’Cathail

Publication year - 2022

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2022.06.003

Subject(s) - medicine , nuclear medicine , rectum , radiation therapy , radiation treatment planning , radiology , surgery

Short course radiotherapy (SCRT) has a low biological prescription dose. Rectal cancer has a dose response relationship and moderate α/β ratio (∼5). We hypothesise hypofractionated dose escalation has radiobiological advantages. We assessed in-silico dose escalation to the primary tumour using a simultaneous integrated boost (SIB) technique.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research